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INTRODUCTION
The intracellular protozoan parasite Trypanosoma cruzi causes Chagas’ disease in humans (Mengel
and Rossi, 1992; Rassi et al., 2010). According to the latest studies, about 5–8 million people are
infected by this parasite around the world, representing a significant global economic burden
(Rassi et al., 2010; Lee et al., 2013; Maguire, 2015). The infection may be divided in acute,
indeterminate and chronic (Mengel and Rossi, 1992; Andrade et al., 2014). The acute disease,
much less frequent nowadays, may be, in most patients, successfully treated with benznidazole, a
drug that efficiently kills the parasite (Rassi et al., 2010). On the other hand, the chronic disease
is by far the most important condition, concerning the total number of infected people. The
chronic disease is characterized by a persistent inflammatory reaction and destruction of host cells,
affecting mainly the peripheral autonomous nervous system in the gastrointestinal tract, the heart
muscle and intracardiac nerves in ∼30–40% of the infected patients, causing the development
of megaesophagus and megacolon, and cardiomegaly associated with progressive and untreatable
heart failure, in addition to an increased frequency of sudden death (Andrade et al., 2014). Yet,
the majority (about 60–70%) of the patients that progress to the chronic phase remain clinically
asymptomatic (Umezawa et al., 2001). Contrarily to most predictions, a large, multicentric,
placebo-controlled, double-blinded clinical trial has shown that treatment with benznidazole has
failed to modify the clinical outcome of chronic Chagas’ disease, in spite of promoting a significant
parasite load reduction (Morillo et al., 2015). these results argue that the treatment concept fails
rather than the anti-parasite effect of the drug itself, suggesting that the presence of the parasite in
the chronic infectionmay not be the only factor responsible for its clinical progression but perhaps a
chronic infection that is inappropriately dealt with by the host defenses would be a major question,
possibly involving a malfunction of regulatory immune mechanisms and autoimmune phenomena
(Mengel and Rossi, 1992; Cardillo et al., 2015). This theoretical framework also accommodatesmost
chronically T. cruzi-infected patients, where this malfunction of regulatory immune mechanisms
would not take place, a balanced immune response would be achieved, and pathology would not
prevail (Cardillo et al., 2015).
REGULATORY T CELLS IN CHAGAS’ DISEASE
Regulatory T cells may curb inflammatory responses, allowing a partially effective anti-parasite
immune response to remain active. In fact, the role of CD4+CD25+Foxp3+ Treg cells during the
chronic T. cruzi infection has been evaluated in mouse and humans. The most recent studies have
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suggested an important role for this T cell subpopulation in
the chronic disease. For instance, recent findings in humans
have shown an increased percentage of Treg cells in chagasic
subjects in the indeterminate chronic phase of the infection
(free of disease) when compared to patients with heart damage,
suggesting an important role for Tregs in Chagas’ disease (de
Araujo et al., 2011).
In addition, in vivo Treg blockade by using nondepleting
monoclonal antibodies to CD25, a marker for these cells,
diminished the myocardial inflammation in the chronic
infection, a finding that was partially ascribed to consequent
increased levels of IL-2 secretion and expansion of CD4+CD25+
regulatory T cells (Nihei et al., 2014; Bonney and Engman, 2015),
providing an indication that the functional activity of Treg cells
might be of critical importance during the chronic phase of the
infection. It should be noted that not all CD4+CD25+foxp3+
T cells in humans are suppressive and a fraction of them have
other effector functions (Miyara et al., 2015). It was recently
described that the expression of CD15s (sialyl Lewis x) identifies
the most suppressive foxp3 high regulatory CD4+CD25+ T
cells (Miyara et al., 2015), discriminating suppressive from
effector CD4+CD25+foxp3+ T cells in humans. Interestingly,
a previously published study has described that the expression
of CD15s was decreased in peripheral blood lymphocytes from
patients with severe Chagas’ disease (Laucella et al., 2001).
Therefore, the expression of CD15s in Tregs may be also relevant
to predict progression to pathology or treatment efficacy in
chagasic patients and further studies concerning this point are
warranted.
Administration of nondepleting anti-CD25 mAb increases
the production of IL-10 by T cells during the chronic T. cruzi
infection in mice (Nihei et al., 2014). It is clear that IL-10 is a
pro-survival cytokine during the acute infection, by controlling
immune hyperactivation and/or by increase immunity to the
parasite (Hunter et al., 1997; Roffe et al., 2012). In Chagas
disease, IL-10 seems to be part of a regulated, nonpathogenic
immune response in patients without cardiomyopathy (Poveda
et al., 2014). These studies suggest that exogenous IL-10
supplementation may be helpful in the control of myocarditis
during Chagas’ disease. Pegylated IL-10 shows an increased
in vivo half-life and helps in the activation of CD8 T cells.
This activity would certainly be important in the control of
residual tissue infection (Oft, 2014). Additionally, pegylated
IL-10, through its potential antifibrotic activity (Mattos et al.,
2012), would be helpful in the control of heart fibrosis, along
T. cruzi infection, making exogenous IL-10 supplementation an
extremely interesting approach to be tested in future studies.
THE INTERLEUKIN 2 AXIS IN IMMUNITY
AND AUTOIMMUNITY
Interleukin-2 (IL-2) was first identified as a growth and
differentiation factor produced and utilized by T cells (Liao
et al., 2013). IL-2 is mainly produced by CD4 T cells and, upon
activation, the production of IL-2 declines along with the T cell
differentiation process (Sallusto et al., 2004). Therefore, memory
T cells produce less IL-2 than naïve T cells. IL-2 is also produced
to a lesser extent by CD8 and NK T cells, some dendritic and
mast cells (Liao et al., 2013) There are two types of receptors
for IL-2 (IL-2R), the high and the low affinity receptors (Liao
et al., 2013). The low affinity receptor is a molecular complex
formed by the association of the beta and the common gamma
chains. The IL-2R beta chain (CD122) is expressed on T cells
and many other cell lineages (Liao et al., 2013). The high affinity
receptor has the addition of the IL-2R alpha chain (CD25) to
the low affinity molecular complex (Liao et al., 2013). CD25 is
mainly expressed in some activated T and B cell subpopulations
as well as NK cells (Liao et al., 2013). IL-2 is of crucial importance
for the T cell proliferation and survival during activation and
differentiation to short-lived memory cells (Liao et al., 2013),
being dispensable after the expression of high levels of the IL-7
receptor or the expression of the IL-15 alpha chain receptor (Liao
et al., 2013). Therefore, it seems that IL-7 and/or IL-15 rather
than IL-2 are the common gamma chain cytokines that help in
the proliferation and maintenance of long-lived memory T cells
(Xu et al., 2014). IL-2 is also a potent cytokine, helping CD8 T
cell activation and differentiation to effector cells, participating
in the process of NK cell activation and development of their
lytic activity (Liao et al., 2013). On the other hand, IL-2 is
involved in the regulatory arm of the immune response, by
augmenting the proliferation of regulatory Foxp3+ T cells and
the reinforcement of the FAS/FAS-L immunoregulatory pathway
(Liao et al., 2013; Kosmaczewska, 2014). These two opposing
functional activities seem to be related to the amount of the
cytokine available in the microenvironment (Kosmaczewska,
2014). Therefore, low amounts of IL-2 would favor the
immunoregulatory pathway, whereas high amounts would be
required for driving effector immune responses (Kosmaczewska,
2014). The role of IL-2 in the immunoregulatory axis of the
immune system is evident in mice and humans where the
availability of IL-2 was reduced (Liao et al., 2013; Kosmaczewska,
2014). For instance, IL-2R-beta or IL-2R–alpha chain knockout
mice develop autoimmune disease and blocking of IL-2 by in
vivo treatment with monoclonal antibody to IL-2 accelerates
autoimmunity in mice (Setoguchi et al., 2005). In humans,
several polymorphisms in the IL-2 pathway have been linked to
type I diabetes and loss of function of Foxp3+ Treg biological
activities. In addition, low levels of circulating IL-2 have been
associated with different autoimmune diseases (Yamanouchi
et al., 2007). Chagasic patients with cardiomyopathy show
decreased production of IL-2 by peripheral blood leucocytes
(Briceno andMosca, 1996). However, serum IL-2 levels have been
reported to increase in chagasic patients with cardiomyopathy
(Poveda et al., 2014). The reasons for the discrepancy are
not clear, but IL-2 may be produced by cells trapped in
other tissues and the presence of serum neutralizing factors,
such as soluble serum CD25RA or anti-cytokine antibodies
generated by a dysregulated immune response may reduce
IL-2-bioactivity (Campen et al., 1988; Tsybikov et al., 2015).
Soluble serum CD25RA and autoantibodies to many different
self-antigens and structures have been described in Chagas
disease (Moretti et al., 2002; Vicco et al., 2013). Autoimmune
diseases usually proceed with lymphopenia and signs of T cell
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senescence (Stockinger et al., 2004; Thewissen et al., 2007). These
characteristics may reflect a dysfunctional thymus and lower
T cell output (Thewissen et al., 2005; Vieira et al., 2008). A
similar picture has emerged for Chagas’ disease. CD4 and CD8 T
cells from chagasic patients carry markers of immunosenescence
and present an exhausted functional phenotype with diminished
production of IL-2 (Albareda et al., 2009, 2015). Increased levels
of immunosenescence correlated with more severe forms of
the disease (Cardillo et al., 1993; Albareda et al., 2009, 2015).
Recent studies have also shown that the thymus is damaged
during T. cruzi infection and therefore, lower numbers of
Tregs and conventional thymic T cell emigrants would reach
peripheral organs. This diminishes T cell renew along the
infection similarly to what has been previously described in
other classical autoimmune diseases (Gonzalez et al., 2016).
Therefore, immunesenescence and autoimmunity would prevail
in about 30% of infected people due to the low numbers and poor
regulatory activity of Tregs that lack IL-2 produced by the pool of
effector conventional T cells.
TOWARD NOVEL STRATEGIES TO TREAT
CHRONIC CHAGAS’ DISEASE
The study of acute and chronic phases of infection with
intracellular pathogens, such as T. cruzi, allows the elucidation
of the mechanisms and conditions that may be targeted to
reprogram the host immune system by using tools that interfere
with components of the regulatory arm of the immune system
machinery. This knowledge would certainly result in a better
understanding of the necessary balance to achieve or reestablish
the health of the host during T. cruzi infection, thus providing
new strategies to treat Chagas’ disease. In this regard, the in vivo
biological activity of nondepleting antibodies to CD25 seems to
reinforce rather than inhibit the function of regulatory T cells
either in mice or humans (Nihei et al., 2014; Huss et al., 2015).
In addition, the in vivo administration of IL-2 or complexes of
IL-2/anti-IL-2 to increase the numbers and functional activity of
regulatory T cells would also be a valuable approach to be used in
Chagas’ disease (Letourneau et al., 2010). Low doses of IL-2 have
already been used successfully in many clinical trials (Matsuoka
et al., 2013; Kosmaczewska, 2014; Humrich et al., 2015). However,
a consensus for the low-dose regimen of IL-2 administration has
not been established and serious concerns about which dose of
IL-2 to use in different clinical conditions remains open to debate
(Perol et al., 2014).
The notion concerning the manipulation of Treg cells either
by antibodies to CD25, IL-2, and/or IL-10 might open up a new
avenue for therapeutic strategies in Chagas’ disease. It should be
noted that more pre-clinical studies, using different strains of
T. cruzi in combination with distinct strains of mice should be
performed in order to better establish these conceptual clinical
interventions, perhaps in addition to more acquiescent schemes
of benznidazole treatment (Bustamante et al., 2014).
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